Global action plan for influenza vaccines

Dr Firdausi Qadri

Director, Centre for Vaccine Sciences (CVS), International Centre for Diarrhoeal Disease and Research, Bangladesh (icddr,b)

Dr. Firdausi Qadri is working in Bangladesh in collaboration with international and national organizations on research related to infectious diseases and vaccine development over the last 25 years.

Trained as a biochemist with specialization in immunology and infectious disease research. Key scientific achievements lie in enteric and diarrheal infections and vaccines including Vibrio cholerae and enterotoxigenic Escherichia coli - major causes of severe diarrhea as well as enteric disease . Emphasis has also been on understanding the immune response in H.pylori infected people in Bangladesh and the responses in patients with typhoid fever as well as vaccinees. Intensive research has been carried out in the field of enteric diseases specifically in the areas of immunology, genomics and proteomic technology and diagnostics and vaccine development. Actively participating in understanding the immunological responses in natural infections as well as in vaccines to better discern factors that need to be improved in available and future formulations.

The laboratory and field based research has involved active collaborations with co-workers including in the USA, Sweden, France, Japan and Bangladesh. Highlights have been projects running for over fifteen years through SIDA as well as NIH based grants including UO1, RO1, RO3, FICRS and training grants to better understand enteric infections leading to vaccine development. Over the last few years, Gates funded projects have been initiated. Also recipient of Grand Challenge Exploration projects on typhoid vaccine as well as rice vaccine study development. Also involved in th immunological component of the Gates funded project on underperformance of oral polio and rotavirus vaccine.

Important ongoing project are ongoing include the “Introduction of Cholera Vaccine in Bangladesh” a feasibility study in Dhaka funded by Bill and Melinda Gates foundation. Novel antigen identification for an enterotoxigenic Escherichia. coli vaccine funded by NIH through grants to the University of Tennessee, Studies of acute and memory immune responses to orally administered vaccines in developing country children and factors that may augment such responses funded by Swedish SIDA. The study of protective immunity to human cholera in Bangladesh, High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development are funded by NIH/NIAID. In recent few years other research projects involve randomized double-blind, placebo-controlled trials to evaluate the safety and immunogenicity of Peru-15 vaccine, administered together with measles vaccine to healthy Bangladeshi infants, mucosal immune responses to oral cholera vaccine Peru-15, studies to enhance and improve immunogenicity of cholera and enterotoxigenic E. coli (ETEC) vaccines, the development of natural immunity to enterotoxigenic E. coli (ETEC) in a cohort of children in Bangladesh, the effect of zinc supplementation and behavior change intervention in improving responses in enteric infections.

She is on advisory panels and members of national and international organizations including fellow of the TWAS- Academy of sciences for the Developing World, Bangladesh Academy of Science, the Infectious Diseases Society of America (FIDSA) and the Bangladesh Medical Research Council and on the advisory panel of the WHO. She is on advisory panels including in research, training and teaching in many Bangladeshi and foreign organizations and institutes. She has published over 200 papers in peer reviewed journals.

Share